Advertisement

Drugs

, Volume 78, Issue 1, pp 147–152 | Cite as

Letermovir: First Global Approval

AdisInsight Report

Abstract

Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Notes

Funding

The preparation of this review was not supported by any external funding.

Compliance with Ethical Standards

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Esther Kim is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/8BFCF060258EFDC2.

References

  1. 1.
    Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection—for healthcare professionals: clinical overview. 2016. https://www.cdc.gov/. Accessed 1 Dec 2017.
  2. 2.
    Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection: about CMV. 2016. https://www.cdc.gov/. Accessed 1 Dec 2017.
  3. 3.
    Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–69.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Maffini E, Giaccone L, Festuccia M, et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016;9(6):585–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Merck. Merck receives FDA approval of PREVYMIS™ (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients [media release]. 9 Nov 2017. http://www.mrknewsroom.com.
  6. 6.
    Merck Sharp & Dohme Corp. Prevymis™ (letermovir) tablet and injection: US Prescribing information. 2017. https://www.fda.gov. Accessed 1 Dec 2017.
  7. 7.
    US FDA. PREVYMIS™ (letermovir) tablet and injection: NDA approval letter. 2017. https://www.fda.gov. Accessed 1 Dec 2017.
  8. 8.
    Merck Canada Inc. Product monograph: PrevymisTM letermovir tablets. 2017. https://pdf.hres.ca/dpd_pm/00041967.PDF. Accessed 1 Dec 2017.
  9. 9.
    Adis Insight. Drug profile: letermovir. 2017. http://adis.springer.com/. Accessed 1 Dec 2017.
  10. 10.
    European Medicines Agency. CHMP summary of positive opinion for Prevymis. 2017. http://www.ema.europa.eu/ema/. Accessed 1 Dec 2017.
  11. 11.
    Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–93.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Merck. AiCuris and Merck enter exclusive worldwide license agreement for investigational portfolio targeting human cytomegalovirus [media release]. 15 Oct 2012. http://www.mrknewsroom.com/.
  13. 13.
    Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54(3):1290–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lischka P, Zhang D, Holder D, et al. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir. Antiviral Res. 2016;132:204–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–3.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213(1):23–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11:1079–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59(6):3140–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kropeit D, von Richter O, Stobernack HP, et al. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2017.  https://doi.org/10.1002/cpdd.388.PubMedGoogle Scholar
  20. 20.
    Kropeit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol. 2017;83(12):2678–86.  https://doi.org/10.1111/bcp.13376.CrossRefPubMedGoogle Scholar
  21. 21.
    Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017.  https://doi.org/10.1056/NEJMoa1706640.Google Scholar
  22. 22.
    Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Stoelben S, Arns W, Renders L, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int. 2014;27(1):77–86.CrossRefPubMedGoogle Scholar
  24. 24.
    US National Library of Medicine. Clinicaltrials.gov. 2017. https://clinicaltrials.gov. Accessed 1 Dec 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations